YM150

DRUG20 trials

Sponsors

Astellas Pharma Inc, Astellas Pharma Europe B.V.

Conditions

Acute Coronary SyndromeArthroplasty, Replacement, HipArthroplasty, Replacement, KneeAtrial FibrillationCaucasianHealthyHealthy Elderly SubjectHealthy Male Subjects

Phase 1

A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150

CompletedNCT01118559

Astellas Pharma IncHealthy, Pharmacokinetics of YM150

Start: 2009-11-30End: 2010-01-31Updated: 2010-05-06

A Study to Compare the Pharmacokinetics of YM150 Formulation-A and Formulation-B

CompletedNCT01125657

Astellas Pharma IncHealthy Volunteer, Pharmacokinetics of YM150

Start: 2010-02-28End: 2010-03-31Updated: 2010-05-25

A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150 Tablet

CompletedNCT01125670

Astellas Pharma IncHealthy Volunteer, Pharmacokinetics of YM150

Start: 2010-02-28End: 2010-04-30Updated: 2010-05-25

A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly Subjects

CompletedNCT01514825

Astellas Pharma IncHealthy Elderly Subject, Pharmacokinetic of YM150

Start: 2006-11-30End: 2007-02-28Updated: 2012-01-24

A Study to Investigate the Effect of YM150 on the Plasma Concentration of Digoxin in Healthy Subjects

CompletedNCT01514812

Astellas Pharma IncHealthy, Pharmacokinetic of Digoxin

Start: 2006-02-28End: 2006-04-30Updated: 2012-01-24

A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the Body

CompletedNCT01655056

Astellas Pharma Europe B.V.Caucasian, Healthy Subjects, Japanese +2

Start: 2006-06-30End: 2006-11-30Updated: 2013-06-26

A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male Subjects

CompletedNCT01657981

Astellas Pharma Europe B.V.Healthy Male Subjects, Pharmacokinetics

Start: 2007-02-28End: 2007-03-31Updated: 2013-06-26

Phase 2

Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)

CompletedNCT00353678

Astellas Pharma IncThromboembolism

Start: 2006-06-30End: 2007-08-31Updated: 2013-03-21

Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement

CompletedNCT00408239

Astellas Pharma IncThromboembolism

Start: 2006-12-31End: 2009-03-31Updated: 2011-12-19

Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

CompletedNCT00448214

Astellas Pharma IncAtrial Fibrillation

Start: 2007-03-31End: 2008-10-31Updated: 2011-12-19

A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery

CompletedNCT00595426

Astellas Pharma IncArthroplasty, Replacement, Knee

Start: 2008-05-31End: 2009-05-31Updated: 2013-03-25

A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery

CompletedNCT00902928

Astellas Pharma Europe B.V.Arthroplasty, Replacement, Hip, Venous Thromboembolism

Start: 2009-04-30End: 2010-08-31Updated: 2015-10-27

Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery

CompletedNCT00913120

Astellas Pharma IncVenous Thromboembolism

Start: 2009-05-31End: 2010-03-31Updated: 2010-06-09

Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery

CompletedNCT00917254

Astellas Pharma IncVenous Thromboembolism

Start: 2009-05-31End: 2010-01-31Updated: 2010-06-16

A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation

CompletedNCT00938730

Astellas Pharma IncAtrial Fibrillation

Start: 2009-06-30End: 2010-09-30Updated: 2011-01-20

Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes

CompletedNCT00994292

Astellas Pharma Europe B.V.Acute Coronary Syndrome

Start: 2009-09-30End: 2011-03-31Updated: 2015-10-19

Phase 3

Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism

CompletedNCT00937820

Astellas Pharma IncVenous Thromboembolism

Start: 2009-06-30End: 2010-12-31Updated: 2011-01-06

Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities

CompletedNCT00937911

Astellas Pharma IncVenous Thromboembolism

Start: 2009-06-30End: 2010-04-30Updated: 2010-06-16

A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

CompletedNCT00942435

Astellas Pharma IncVenous Thromboembolism

Start: 2009-06-30End: 2010-04-30Updated: 2010-06-16

YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness

CompletedNCT01028950

Astellas Pharma IncVenous Thromboembolism

Start: 2009-05-31End: 2010-04-30Updated: 2010-06-16

Related Papers

A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2).

2015-07-158 citations

Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3)

Thrombosis and Haemostasis2013-10-1712 citations

Darexaban (YM150) prevents venous thromboembolism in Japanese patients undergoing major abdominal surgery: Phase III randomized, mechanical prophylaxis-controlled, open-label study.

2012-07-0218 citations

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.

2011-08-30123 citations